NCT06115512终止3 期
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Lntervertebral Local Administration of AGA111 in Patients With Degenerative Disc Disease Undergoing Lumbar Lnterbody Fusion
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 412
- 试验地点
- 35
- 主要终点
- Overall success rate: Proportion of subjects who achieve overall success.
研究概览
简要总结
The primary objective of the study is to assess the overall efficacy of a single intervertebral local administration of AGA111 in patients with degenerative disc disease undergoing lumbar interbody fusion.
详细描述
This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single intervertebral local administration of AGA111 in patients with degenerative disc disease undergoing lumbar interbody fusion. About 400 subjects who meet the eligibility criteria will be randomly assigned to the following two treatment groups in a 1:1 ratio.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Has degenerative disc disease of L3-S1 with low back pain, with or without a history of radiating leg or buttock pain, paresthesia, numbness or weakness secondary to radiculopathy of the corresponding spinal segment;
- •Has radiographic evidence (e.g., X-ray and CT/magnetic resonance imaging MRI) of degenerative disc disease;
- •Adults ≥ 18 and ≤ 80 years of age and skeletally mature at the time of surgery;
- •Plan to undergo a single-level lumbar interbody fusion;
- •Preoperative ODI score ≥ 30;
- •Has not respond to conservative treatment (e.g, bed rest, physical therapy, drugs, local injections, manipulation and other non-surgical treatments) for a period of at least 3 months;
- •Willing and able to comply with the protocol and able to understand and sign the subject's informed consent form (ICF) ;
- •Female subjects of child-bearing potential must agree to use a highly effective method of birth control during the study and for 1 year after the administration of investigational drug, and must have a negative pregnancy test prior to the randomization.
排除标准
- •Has undergone other decompression, fusion, and/or other non-fusion spinal surgery at the spinal segment intended to undergo the surgery prior to the screening (except for transforaminal endoscopic discectomy);
- •Known other significant lumbar instability;
- •Lumbar scoliosis > 30 degrees (evaluated by investigators);
- •Presence of active malignancy or prior history of malignancy;
- •Overt or active infection, either local to surgical space or systemic;
- •Patients with a dual-energy X-ray absorption (DXA) total hip T-score ≤ -3.0;
- •Body weight index (BMI) <18.5 kg/m2 or BMI > 35 kg/m2;
- •Have received other treatments affecting fusion surgery, such as radiotherapy near the surgical site;
- •Presence of other co-morbidities of the spine or upper/lower extremities that may affect the investigator's assessment of the lumbosacral nervous system and/or pain;
- •Presence of mental disease or psychiatric condition that interferes with the patient's self-assessment of function, pain, or quality of life;
- •History of progressive osseous heteroplasia or fibrodysplasia ossificans progressiva;
- •Known hypersensitivity or allergy to bone morphogenetic protein (BMP) products or their excipient; and/or instrumentation materials in surgery, e.g., titanium, titanium alloy, cobalt chrome, cobalt chrome alloy, or polyetheretherketone (PEEK);
- •Pregnant or lactating women; or plan to become pregnant within 1 year following the study surgery.
- •Other conditions that, in the opinion of the investigator, would interfere with the subject's ability to comply with the protocol, and other conditions that will make the subject inappropriate for participation in the study as judged by the investigator.
研究组 & 干预措施
Placebo
Placebo Comparator
Placebo in ABC is locally delivered at the intervertebral space.
干预措施: Placebo (Drug)
AGA111
Experimental
AGA111 in autologous blood coagulum (ABC) is locally delivered at the intervertebral space.
干预措施: AGA111 (Drug)
结局指标
主要结局
Overall success rate: Proportion of subjects who achieve overall success.
时间窗: Up to 52 weeks
次要结局
- Success rate of radiographic fusion(Up to 52 weeks)
- Mean change of ODI (Oswestry Disability Index) score(Up to 52 weeks)
研究者
研究点 (35)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar LinesModerate to Severe Glabellar LinesNCT02353871Ipsen185
已完成
3 期
Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar LinesGlabellar LinesNCT02493946Ipsen600
撤回
3 期
Study Comparing 3 Formulations to Evaluate the Efficacy and Safety of the Inflammatory Symptoms of the Upper Respiratory Tract, in Children Between 2 and 6 Years OldCommon ColdNCT00967759Ache Laboratorios Farmaceuticos S.A.
终止
3 期
Patiromer Trial in CKD Stage IIIB to VHyperkalemiaNCT05786469Mario Negri Institute for Pharmacological Research2
已完成
不适用
Evaluating the Effectiveness of a Cognitive Behavioral Intervention (CBI)Adolescent BehaviorDental PlaqueCognitive ChangeGingivitisNCT05782348Howard University150